论文部分内容阅读
目的:探讨p130Cas在膀胱尿路上皮癌(BUC)中的表达及其临床意义。方法:78例手术标本中有70例BUC组织和8例癌旁正常膀胱黏膜组织。在BUC组织中包括非肌层浸润性膀胱尿路上皮癌(NMIBUC)27例,肌层浸润性膀胱尿路上皮癌(MIBUC)43例;其中低度恶性倾向尿路上皮乳头状瘤(PUNLMP)和低分级尿路上皮癌共38例,高分级尿路上皮癌32例。采用量子点免疫荧光组织化学方法检测所有标本中p130Cas的表达情况。结果:p130Cas在NMIBUC和MIBUC组织中表达的阳性率分别为40.7%和65.1%(P<0.05);在PUNLMP及低分级尿路上皮癌和高分级尿路上皮癌中的阳性表达率分别为44.7%和68.8%(P<0.05)。此外,p1 30Cas在BUC中的表达水平与患者的性别、年龄、肿瘤的数目、大小无显著相关性(P均>0.05)。结论:p130Cas与膀胱肿瘤的浸润和转移存在联系,有可能作为评估膀胱肿瘤恶性程度和预后的有效参考指标。
Objective: To investigate the expression of p130Cas in bladder urothelial carcinoma (BUC) and its clinical significance. Methods: There were 70 cases of BUC and 78 cases of normal bladder mucosa in 78 cases of surgical specimens. Twenty-seven cases of non-muscular invasive bladder urothelial carcinoma (NMIBUC) and 43 cases of muscular-invasive bladder urothelial carcinoma (MIBUC) were included in the BUC tissues. Among them, low-grade malignant prolapsed urothelial papilloma (PUNLMP) And low-grade urothelial carcinoma in 38 cases, high-grade urothelial carcinoma in 32 cases. Quantitative dot immunofluorescence histochemistry was used to detect the expression of p130Cas in all specimens. Results: The positive rates of p130Cas expression in NMIBUC and MIBUC tissues were 40.7% and 65.1%, respectively (P <0.05). The positive rates of p130Cas in PUNLMP, low-grade urothelial carcinoma and high-grade urothelial carcinoma were 44.7 % And 68.8% (P <0.05). In addition, the expression level of p130Cas in BUC was not significantly correlated with the gender, age, tumor number and size (P> 0.05). Conclusion: p130Cas is associated with invasion and metastasis of bladder neoplasm, which may serve as a useful reference index for assessing the malignancy and prognosis of bladder neoplasms.